Good MorningThe equities markets got a boost on Friday after a stronger than expected non-farm payrolls report. The headline figure of 4.8 million was far above analysts’ estimates and has added fuel to the market’s melt-up. The down shot is that news related to the COVID-19 pandemic helped cap gains. Word of new record levels of cases in the U.S. has the markets worried about another round of economic interruption and the impact on earrings.
Despite the worry, Friday’s action was bullish as it set a new high and closed above the previous day’s action. The candle, a small doji, is a sign of indecision but one that will likely lead to higher prices over the next few weeks. With the reopening underway, economic data is going to be strong and that will drive bullish sentiment as the 2nd quarter earnings cycle gets underway.
Featured: 25 candidates screened. 5 made it. (Ad) 
|
Markets | |
New York-based Drive Shack (NYSE:DS) owns and operates innovative golf entertainment venues in the U.S. Its "social driving ranges", which are popular with the millennial and Generation Z crowd, put golf-related challenges at the center of a good excuse for people to get together and eat, drink, a... Read the Full Story |
|
From Our Partners | | Barrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourmile, Goldrush, and Cortez Hills, a region that could hold as much as 60 million ounces of gold.
Bordering Fourmile and less than a mile from Goldrush sits a little-known explorer now moving from historical data toward active exploration, setting targets and preparing for a maiden drilling program.
With gold trading near record highs, this could be a pivotal stage for an overlooked name in the district. | | See why this overlooked gold explorer could be entering its most important stage |
|
Markets | |
Vaccines are big business. No matter what else you could say about them—and you could say plenty, starting with “they're one of the greatest things modern civilization has to offer” and ending with “they're eventually going to kill us all”—it is thoroughly unden... Read the Full Story |
|
Markets | |
So...how do you feel about risk? There are investors out there who can't get enough of the stuff, and invest as Richard Branson lived for a good chunk of the last couple decades. There are others, meanwhile, who'd keep it at the barest minimum possible. For investors who crave risk, Tesla (NASDAQ:... Read the Full Story |
|
From Our Partners | | A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years.
While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million.
One company controls the entire supply chain behind this discovery. | | See the ticker behind this Grand Canyon energy breakthrough now |
|
Markets | |
The big question heading into FedEx's (NYSE:FDX) fourth-quarter report was whether a pandemic-driven online shopping spree would outweigh lower business shipping volumes. The answer is a resounding yes.
The delivery and logistics giant announced a 2% decline in revenue to $17.4 billion but adjust... Read the Full Story |
|
Markets | | Pool Corporation (NASDAQ: POOL) stock increased by more than 2% yesterday; shares are now less than 1% away from breaking out to fresh all-time highs.
POOL distributes swimming pool maintenance products, equipment, and building materials through its sales centers. Some of the company’s produc... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Markets | |
Sometimes, keeping things simple in the stock market is the best way to profit. If you notice a particular industry or stock that has been regularly gaining, riding the trend can be a very lucrative strategy. For example, take a look at a stock like Sea Limited (NYSE:SE). The e-commerce company&rs... Read the Full Story |
|
Markets | |
The results are in. The Federal Reserve conducted its annual stress tests on the nation’s banks last week. As a reminder, the objective of the stress tests is to look at a bank’s liquidity under a worst case scenario. Wells Fargo (NYSE:WFC) was one of 33 banks with more than $100 billi... Read the Full Story |
|
Markets | |
Gilead Sciences (NASDAQ:GILD) is struggling to hold onto gains in midday trading following the release of pricing for its Covid-19 treatment remdesivir. What would normally be seen as a home run for investors is meeting headwinds as consumer groups cry foul.
The company announced patients with pr... Read the Full Story |
|
Markets | |
Facebook (NASDAQ:FB) stock continues to decline during Monday trading as more advertisers continue to join a growing boycott of the social media platform. The sell-off started on Friday, June 26 when Facebook stock dropped 8.3%. The two-day decline has decreased Facebook’s market value by $6... Read the Full Story |
|
Markets | |
All it takes is one successful cyberattack to cause significant damage to a company’s reputation for protecting its customer and its internal data. In today’s increasingly technology-dominated world, the ability to provide reliable cybersecurity services is becoming an essential servic... Read the Full Story |
|
The Early Bird Stock Of The Day Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. | | View Today's Stock Pick |
|
